Published in Exp Mol Pathol on July 06, 2007
The role of antigen presenting cells in multiple sclerosis. Biochim Biophys Acta (2010) 1.38
Two-photon laser scanning microscopy imaging of intact spinal cord and cerebral cortex reveals requirement for CXCR6 and neuroinflammation in immune cell infiltration of cortical injury sites. J Immunol Methods (2009) 1.29
A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain (2008) 1.25
MHC class I-restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8⁺ T cells. Nat Immunol (2013) 1.10
Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS. Adv Exp Med Biol (2012) 0.80
FLT-3 expression and function on microglia in multiple sclerosis. Exp Mol Pathol (2010) 0.79
RGC-32 is a novel regulator of the T-lymphocyte cell cycle. Exp Mol Pathol (2015) 0.75
Axonal transection in the lesions of multiple sclerosis. N Engl J Med (1998) 12.21
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Dendritic cells in a mature age. Nat Rev Immunol (2006) 5.03
Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med (2005) 4.67
Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med (2005) 4.43
Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med (2005) 4.42
Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol (2001) 4.06
CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol (2007) 3.77
The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron (2006) 3.55
Multiple sclerosis: a two-stage disease. Nat Immunol (2001) 3.20
Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol (2002) 2.93
Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol (2001) 2.38
APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest (2007) 2.28
Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol (2004) 1.83
Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J Comp Neurol (1999) 1.81
Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci (2002) 1.80
Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain (2001) 1.78
A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci (1979) 1.73
Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am J Pathol (2000) 1.72
Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med (2004) 1.70
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol (2004) 1.69
Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J Neuropathol Exp Neurol (2006) 1.52
Human microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells. J Leukoc Biol (1994) 1.44
The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. Neuroscience (1996) 1.41
A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology (1995) 1.38
Dendritic cell transmigration through brain microvessel endothelium is regulated by MIP-1alpha chemokine and matrix metalloproteinases. J Immunol (2007) 1.37
Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int Immunol (2006) 1.35
Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J Neuropathol Exp Neurol (2005) 1.31
Innate and adaptive immune responses of the central nervous system. Crit Rev Immunol (2006) 1.28
Dendritic cell chemotaxis and transendothelial migration are induced by distinct chemokines and are regulated on maturation. Eur J Immunol (1998) 1.16
Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain (2006) 1.16
Dendritic cells and dendritic-like microglia in focal cortical ischemia of the mouse brain. J Neuroimmunol (2002) 1.15
Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci U S A (2005) 1.14
Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol (2001) 1.11
CNS dendritic cells: critical participants in CNS inflammation? Neurochem Int (2006) 1.09
Dendritic cells are present in ischemic brain after permanent middle cerebral artery occlusion in the rat. Stroke (2002) 1.05
Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system. Ann Neurol (2006) 1.00
Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology (2005) 0.97
Multiple sclerosis: trapped in deadly glue. Nat Med (2005) 0.97
Challenge with innate and protein antigens induces CCR7 expression by microglia in vitro and in vivo. Glia (2006) 0.97
Experimental autoimmune encephalomyelitis develops in CC chemokine receptor 7-deficient mice with altered T-cell responses. Scand J Immunol (2006) 0.94
CD83-positive dendritic cells are present in occasional perivascular cuffs in multiple sclerosis lesions. Mult Scler (2003) 0.93
Elevated expression of CCR5 by myeloid (CD11c+) blood dendritic cells in multiple sclerosis and acute optic neuritis. Clin Exp Immunol (2002) 0.90
Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis. J Immunol (2004) 0.89
Oligodendrocyte cell death in pathogenesis of multiple sclerosis: Protection of oligodendrocytes from apoptosis by complement. J Rehabil Res Dev (2006) 0.89
Expression of Flt3-ligand by the endothelial cell. Leukemia (2000) 0.88
Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exp Immunol (2006) 0.86
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
Tract probability maps in stereotaxic spaces: analyses of white matter anatomy and tract-specific quantification. Neuroimage (2007) 5.23
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology (2006) 4.72
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain (2011) 3.48
Photoreceptor layer thinning in idiopathic Parkinson's disease. Mov Disord (2014) 3.36
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol (2009) 3.35
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A (2006) 3.13
A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions. Neuroimage (2009) 3.07
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest (2003) 3.02
Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol (2010) 2.99
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol (2010) 2.96
Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol (2012) 2.79
Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology (2012) 2.54
Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology (2012) 2.48
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol (2009) 2.43
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurol (2013) 2.22
Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain (2011) 2.21
Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol (2008) 2.20
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol (2005) 2.08
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology (2013) 2.06
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology (2005) 2.06
High resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord. Brain (2007) 2.03
Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler (2011) 2.02
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol (2010) 1.97
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol (2009) 1.85
Diffusion tensor magnetic resonance imaging of Wallerian degeneration in rat spinal cord after dorsal root axotomy. J Neurosci (2009) 1.79
Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers. J Neurosci (2010) 1.69
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Retinal layer segmentation of macular OCT images using boundary classification. Biomed Opt Express (2013) 1.67
Multiparametric magnetic resonance imaging analysis of the corticospinal tract in multiple sclerosis. Neuroimage (2007) 1.62
Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics (2011) 1.57
Death by transposition - the enemy within? Bioessays (2013) 1.53
Transnasal ultrathin endoscopy for placement of a long intestinal tube in patients with intestinal obstruction. Gastrointest Endosc (2008) 1.52
Multifocal visual evoked potentials are influenced by variable contrast stimulation in MS. Neurology (2012) 1.51
Optic nerve head component responses of the multifocal electroretinogram in MS. Neurology (2013) 1.46
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol (2009) 1.43
Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A (2013) 1.41
Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch Neurol (2005) 1.40
Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain (2009) 1.38
In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques. J Neurol (2012) 1.36
Pulsed magnetization transfer imaging with body coil transmission at 3 Tesla: feasibility and application. Magn Reson Med (2006) 1.34
Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem (2006) 1.31
Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol (2004) 1.31
Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler (2010) 1.29
Axonal protective effects of the myelin-associated glycoprotein. J Neurosci (2009) 1.29
Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res (2011) 1.28
Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes. J Immunol (2007) 1.27
Automated vs. conventional tractography in multiple sclerosis: variability and correlation with disability. Neuroimage (2009) 1.27
Revisiting brain atrophy and its relationship to disability in multiple sclerosis. PLoS One (2012) 1.26
PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis. CNS Drugs (2012) 1.25
A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain (2008) 1.25
Reproducibility of optical coherence tomography in multiple sclerosis. Arch Neurol (2008) 1.25
Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest (2014) 1.24
RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem (2001) 1.23
Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis. Arch Neurol (2008) 1.20
Granzyme B mediates neurotoxicity through a G-protein-coupled receptor. FASEB J (2006) 1.19
The role of the complement system in innate immunity. Immunol Res (2005) 1.19
RGC-32 mediates transforming growth factor-beta-induced epithelial-mesenchymal transition in human renal proximal tubular cells. J Biol Chem (2009) 1.18
NMDA receptor signaling in oligodendrocyte progenitors is not required for oligodendrogenesis and myelination. J Neurosci (2011) 1.18
One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis. Am J Ophthalmol (2011) 1.17
Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci U S A (2005) 1.14
Quantitative measures detect sensory and motor impairments in multiple sclerosis. J Neurol Sci (2011) 1.14
Reconstruction of the human cerebral cortex robust to white matter lesions: method and validation. Hum Brain Mapp (2013) 1.14
Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol (2008) 1.14
Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol (2011) 1.13
Agar-gelatin for embedding tissues prior to paraffin processing. Biotechniques (2007) 1.11
Expression of the antimicrobial peptide alpha-defensin/cryptdins in intestinal crypts decreases at the initial phase of intestinal inflammation in a model of inflammatory bowel disease, IL-10-deficient mice. Inflamm Bowel Dis (2010) 1.11
C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem (2006) 1.11
Overexpression of RGC-32 in colon cancer and other tumors. Exp Mol Pathol (2005) 1.10
Status epilepticus enhances tonic GABA currents and depolarizes GABA reversal potential in dentate fast-spiking basket cells. J Neurophysiol (2013) 1.10
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol (2008) 1.10
IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest (2005) 1.10
The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials. PLoS One (2011) 1.09
Pleiotrophin regulates the retention and self-renewal of hematopoietic stem cells in the bone marrow vascular niche. Cell Rep (2012) 1.08
High b-value q-space diffusion-weighted MRI of the human cervical spinal cord in vivo: feasibility and application to multiple sclerosis. Magn Reson Med (2008) 1.08
Transcription elongation factor S-II maintains transcriptional fidelity and confers oxidative stress resistance. Genes Cells (2003) 1.08
OASIS is Automated Statistical Inference for Segmentation, with applications to multiple sclerosis lesion segmentation in MRI. Neuroimage Clin (2013) 1.08
Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis. Mult Scler (2012) 1.08
The role of complement activation in atherosclerosis. Immunol Res (2004) 1.07
Stimulation of RNA polymerase II transcript cleavage activity contributes to maintain transcriptional fidelity in yeast. Genes Cells (2007) 1.07
Probing mouse brain microstructure using oscillating gradient diffusion MRI. Magn Reson Med (2011) 1.07
Retinal ganglion cell layer volumetric assessment by spectral-domain optical coherence tomography in multiple sclerosis: application of a high-precision manual estimation technique. J Neuroophthalmol (2011) 1.07
Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis. Neurology (2013) 1.06
Cutting edge: The transcription factor Kruppel-like factor 4 regulates the differentiation of Th17 cells independently of RORγt. J Immunol (2010) 1.05
Low-dose exposure to inorganic mercury accelerates disease and mortality in acquired murine lupus. Environ Health Perspect (2003) 1.05
The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription. Immunol Res (2005) 1.04